CN116133674A - 癌症的治疗 - Google Patents

癌症的治疗 Download PDF

Info

Publication number
CN116133674A
CN116133674A CN202180059063.2A CN202180059063A CN116133674A CN 116133674 A CN116133674 A CN 116133674A CN 202180059063 A CN202180059063 A CN 202180059063A CN 116133674 A CN116133674 A CN 116133674A
Authority
CN
China
Prior art keywords
lag
protein
derivative
subject
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059063.2A
Other languages
English (en)
Chinese (zh)
Inventor
弗雷德里克·特里贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immutep SAS
Original Assignee
Immutep SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008037.0A external-priority patent/GB202008037D0/en
Priority claimed from GBGB2018062.6A external-priority patent/GB202018062D0/en
Application filed by Immutep SAS filed Critical Immutep SAS
Publication of CN116133674A publication Critical patent/CN116133674A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202180059063.2A 2020-05-28 2021-03-24 癌症的治疗 Pending CN116133674A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2008037.0A GB202008037D0 (en) 2020-05-28 2020-05-28 Treatment of cancer
GB2008037.0 2020-05-28
RU2020131384 2020-09-23
RU2020131384A RU2020131384A (ru) 2020-05-28 2020-09-23 Лечение рака
GB2018062.6 2020-11-17
GBGB2018062.6A GB202018062D0 (en) 2020-11-17 2020-11-17 Treatment of cancer
PCT/EP2021/057588 WO2021239292A1 (en) 2020-05-28 2021-03-24 Treatment of cancer

Publications (1)

Publication Number Publication Date
CN116133674A true CN116133674A (zh) 2023-05-16

Family

ID=75362569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059063.2A Pending CN116133674A (zh) 2020-05-28 2021-03-24 癌症的治疗

Country Status (11)

Country Link
US (1) US20230210946A1 (https=)
EP (1) EP4157313A1 (https=)
JP (1) JP2023527209A (https=)
KR (1) KR20230028321A (https=)
CN (1) CN116133674A (https=)
AU (1) AU2021280214A1 (https=)
BR (1) BR112022024179A2 (https=)
CA (1) CA3184309A1 (https=)
IL (1) IL298507A (https=)
MX (1) MX2022014909A (https=)
WO (1) WO2021239292A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475955A1 (en) * 2022-02-11 2024-12-18 Immutep S.A.S. Treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044273A2 (en) * 2007-10-05 2009-04-09 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN105916504A (zh) * 2013-12-19 2016-08-31 伊缪泰普有限公司 用于治疗癌症的组合制剂
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP2021534177A (ja) * 2018-08-16 2021-12-09 ジー１ セラピューティクス， インコーポレイテッド 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044273A2 (en) * 2007-10-05 2009-04-09 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US20110008331A1 (en) * 2007-10-05 2011-01-13 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN105916504A (zh) * 2013-12-19 2016-08-31 伊缪泰普有限公司 用于治疗癌症的组合制剂
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRYSTELLE BRIGNONE1等: "First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 8, no. 1, 23 July 2010 (2010-07-23), pages 1, XP021078895, DOI: 10.1186/1479-5876-8-71 *
GLOBE NEWSWIRE: "Imutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020", Retrieved from the Internet <URL:https://www.biospace.com/article/releases/imutep-reports-supportive-efficacy-data-from-the-phase-iib-aipac-study-overall1-survival-data-expected-in-late-2020> *
LUC DIRIX等: "AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer", FUTURE ONCOL, vol. 15, no. 17, 1 January 2019 (2019-01-01), pages 5 *

Also Published As

Publication number Publication date
KR20230028321A (ko) 2023-02-28
JP2023527209A (ja) 2023-06-27
US20230210946A1 (en) 2023-07-06
IL298507A (en) 2023-01-01
AU2021280214A1 (en) 2023-02-02
EP4157313A1 (en) 2023-04-05
CA3184309A1 (en) 2021-12-02
MX2022014909A (es) 2023-03-06
BR112022024179A2 (pt) 2023-02-07
WO2021239292A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
KR20230151057A (ko) 혈소판 유래 성장 인자 수용체 알파의 유전적 이상과 연관된 암 치료를 위한 1-[4-브로모-5-[1-에틸-7-(메틸아미노)-2-옥소-1,2-다이히드로-1,6-나프티리딘-3-일]-2-플루오로페닐]-3-페닐우레아 및 유사체의 용도
EP3089749B1 (en) Combined preparations for the treatment of cancer
Lee et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
Pham et al. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1–7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy
KR20020000557A (ko) 항종양제의 효능 증강방법
CN116133674A (zh) 癌症的治疗
JP2026001134A (ja) ミトキサントロン塩酸塩リポソームの応用
CN117500524A (zh) 三重组合疗法
KR101560339B1 (ko) 의약 조성물 또는 조합제
US20250368714A1 (en) Treatment of cancer
KR102624844B1 (ko) 암의 향상된 치료
Seifart et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC)
AU2014225496B2 (en) Kits and methods for the treatment of cancer using gliadin peptides
US20230181633A1 (en) Methods of treating cancer using a combination of tumor membrane vesicles and metformin
Scagliotti et al. Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
Martoni et al. Planned sequence of gemcitabine followed by vinorelbine in the treatment of elderly patients with advanced non-small cell lung cancer
CN118804760A (zh) 癌症的治疗
Shin et al. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma
HK40082294A (en) Uses of mitoxantrone hydrochloride liposome
Czyżykowski et al. Palliative systemic treatment of patients with pancreatic cancer—should reimbursement of nab-paclitaxel change the current management paradigm?
HK40011073B (en) Combined preparations for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination